Quantification of Proinsulin in Human Plasma by Proteolysis-Aided Peptide Immunoaffinity-Liquid Chromatography-Tandem Mass Spectrometry

BACKGROUND: Plasma proinsulin concentrations are used to investigate hypoglycemia. They have also been proposed as a marker of β-cell function, particularly as a ratio with C-peptide. Immunoassays remain the primary method for measuring proinsulin despite potential limitations. Mass spectrometry-based assays have been described, but are semiquantitative or rely on nano-flow liquid chromatography. We aimed to develop a liquid chromatography-tandem mass spectrometry assay (LC-MS/MS) at typical clinical laboratory flow rates to quantify proinsulin and its partially processed forms in human plasma and ensure accuracy over time with distributable well-characterized calibrators. METHODS: Sample preparation consists of protein precipitation, Glu-C digestion, peptide immunoaffinity enrichment, and LC-MS/MS analysis of 2 surrogate peptides: RGFFYTPKTRREAE spans the cleavage site for des-31,32-proinsulin and GSLQKRGIVE spans the site for des-64,65-proinsulin. A purified protein calibration material was characterized (HPLC and amino acid analysis) and used to value-assign a matrix-matched single-point calibration material. RESULTS: Within-batch and between-batch imprecision were ≤12.2% and ≤16.4%, respectively. The assay was linear from 0.14 to 53.5 pM and 1.1 to 91.6 pM, with a lower limit of the measuring interval of 2.8 and 8.8 pM for RGFFYTPKTRREAE and GSLQKRGIVE, respectively. The concentration of des-31,32-proinsulin increased more during childhood than intact proinsulin. Participants with type 1 diabetes-associated autoantibodies had higher proinsulin-to-C-peptide ratios. Method comparison with 2 commercial immunoassays revealed variable cross-reactivity with insulin. CONCLUSION: The validated assay is robust and will be a useful tool for advancing studies of β-cell function. A detailed standard operating procedure, well-characterized calibration material, and monoclonal antibodies are available for adoption in other laboratories.

Authors

Institutions

Publication Details

Journal
Clinical Chemistry
Published
2026-08-21
DOI
https://doi.org/10.1093/clinchem/hvag105
Primary Topic
Diabetes and associated disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Quantification of Proinsulin in Human Plasma by Proteolysis-Aided Peptide Immunoaffinity-Liquid Chromatography-Tandem Mass Spectrometry

Jessica O. Becker, Andrew N. Hoofnagle, Cate Speake, Elisha Goonatilleke et al.
Clinical Chemistry
Diabetes and associated disorders
article

Quantification of Proinsulin in Human Plasma by Proteolysis-Aided Peptide Immunoaffinity-Liquid Chromatography-Tandem Mass Spectrometry

Jessica O. Becker, Andrew N. Hoofnagle, Cate Speake, Elisha Goonatilleke, Huu‐Hien Huynh, Lili Barahona‐Carrillo, Sara K Shijo, Cecilia S. Lee, Lisa Johnson, Katrina Forrest, Michael J MacCoss
article en

Abstract

BACKGROUND: Plasma proinsulin concentrations are used to investigate hypoglycemia. They have also been proposed as a marker of β-cell function, particularly as a ratio with C-peptide. Immunoassays remain the primary method for measuring proinsulin despite potential limitations. Mass spectrometry-based assays have been described, but are semiquantitative or rely on nano-flow liquid chromatography. We aimed to develop a liquid chromatography-tandem mass spectrometry assay (LC-MS/MS) at typical clinical laboratory flow rates to quantify proinsulin and its partially processed forms in human plasma and ensure accuracy over time with distributable well-characterized calibrators. METHODS: Sample preparation consists of protein precipitation, Glu-C digestion, peptide immunoaffinity enrichment, and LC-MS/MS analysis of 2 surrogate peptides: RGFFYTPKTRREAE spans the cleavage site for des-31,32-proinsulin and GSLQKRGIVE spans the site for des-64,65-proinsulin. A purified protein calibration material was characterized (HPLC and amino acid analysis) and used to value-assign a matrix-matched single-point calibration material. RESULTS: Within-batch and between-batch imprecision were ≤12.2% and ≤16.4%, respectively. The assay was linear from 0.14 to 53.5 pM and 1.1 to 91.6 pM, with a lower limit of the measuring interval of 2.8 and 8.8 pM for RGFFYTPKTRREAE and GSLQKRGIVE, respectively. The concentration of des-31,32-proinsulin increased more during childhood than intact proinsulin. Participants with type 1 diabetes-associated autoantibodies had higher proinsulin-to-C-peptide ratios. Method comparison with 2 commercial immunoassays revealed variable cross-reactivity with insulin. CONCLUSION: The validated assay is robust and will be a useful tool for advancing studies of β-cell function. A detailed standard operating procedure, well-characterized calibration material, and monoclonal antibodies are available for adoption in other laboratories.

Clinical Chemistry
Seattle Children's Hospital (US), University of Washington (US), Washington University in St. Louis (US), Kidney Research UK (GB), Society of Interventional Radiology (US)
NHS Innovation Accelerator, Norges Idrettshøgskole, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Openalex Percentile: Top 10%
Diabetes and associated disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.